These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 16722622)
1. Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site. Gopalsamy A; Chopra R; Lim K; Ciszewski G; Shi M; Curran KJ; Sukits SF; Svenson K; Bard J; Ellingboe JW; Agarwal A; Krishnamurthy G; Howe AY; Orlowski M; Feld B; O'Connell J; Mansour TS J Med Chem; 2006 Jun; 49(11):3052-5. PubMed ID: 16722622 [TBL] [Abstract][Full Text] [Related]
2. HCV NS5B polymerase-bound conformation of a soluble sulfonamide inhibitor by 2D transferred NOESY. Yannopoulos CG; Xu P; Ni F; Chan L; Pereira OZ; Reddy TJ; Das SK; Poisson C; Nguyen-Ba N; Turcotte N; Proulx M; Halab L; Wang W; Bédard J; Morin N; Hamel M; Nicolas O; Bilimoria D; L'Heureux L; Bethell R; Dionne G Bioorg Med Chem Lett; 2004 Nov; 14(21):5333-7. PubMed ID: 15454222 [TBL] [Abstract][Full Text] [Related]
3. Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase. Nittoli T; Curran K; Insaf S; DiGrandi M; Orlowski M; Chopra R; Agarwal A; Howe AY; Prashad A; Floyd MB; Johnson B; Sutherland A; Wheless K; Feld B; O'Connell J; Mansour TS; Bloom J J Med Chem; 2007 May; 50(9):2108-16. PubMed ID: 17402724 [TBL] [Abstract][Full Text] [Related]
4. II. Novel HCV NS5B polymerase inhibitors: discovery of indole C2 acyl sulfonamides. Anilkumar GN; Selyutin O; Rosenblum SB; Zeng Q; Jiang Y; Chan TY; Pu H; Wang L; Bennett F; Chen KX; Lesburg CA; Duca J; Gavalas S; Huang Y; Pinto P; Sannigrahi M; Velazquez F; Venkatraman S; Vibulbhan B; Agrawal S; Ferrari E; Jiang CK; Huang HC; Shih NY; George Njoroge F; Kozlowski JA Bioorg Med Chem Lett; 2012 Jan; 22(1):713-7. PubMed ID: 22104146 [TBL] [Abstract][Full Text] [Related]
5. Discovery of benzophosphadiazine drug candidate IDX375: A novel hepatitis C allosteric NS5B RdRp inhibitor. Paparin JL; Amador A; Badaroux E; Bot S; Caillet C; Convard T; Da Costa D; Dukhan D; Griffe L; Griffon JF; LaColla M; Leroy F; Liuzzi M; Giulia Loi A; McCarville J; Mascia V; Milhau J; Onidi L; Pierra C; Rahali R; Rosinosky E; Sais E; Seifer M; Surleraux D; Standring D; Dousson CB Bioorg Med Chem Lett; 2017 Jun; 27(11):2634-2640. PubMed ID: 28416131 [TBL] [Abstract][Full Text] [Related]
6. Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors. Ikegashira K; Oka T; Hirashima S; Noji S; Yamanaka H; Hara Y; Adachi T; Tsuruha J; Doi S; Hase Y; Noguchi T; Ando I; Ogura N; Ikeda S; Hashimoto H J Med Chem; 2006 Nov; 49(24):6950-3. PubMed ID: 17125247 [TBL] [Abstract][Full Text] [Related]
7. Identification and biological evaluation of a series of 1H-benzo[de]isoquinoline-1,3(2H)-diones as hepatitis C virus NS5B polymerase inhibitors. Ontoria JM; Rydberg EH; Di Marco S; Tomei L; Attenni B; Malancona S; Martin Hernando JI; Gennari N; Koch U; Narjes F; Rowley M; Summa V; Carroll SS; Olsen DB; De Francesco R; Altamura S; Migliaccio G; Carfì A J Med Chem; 2009 Aug; 52(16):5217-27. PubMed ID: 19877603 [TBL] [Abstract][Full Text] [Related]
8. Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors. May MM; Brohm D; Harrenga A; Marquardt T; Riedl B; Kreuter J; Zimmermann H; Ruebsamen-Schaeff H; Urban A Antiviral Res; 2012 Aug; 95(2):182-91. PubMed ID: 22580131 [TBL] [Abstract][Full Text] [Related]
9. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles. Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065 [TBL] [Abstract][Full Text] [Related]
10. Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors. Gopalsamy A; Lim K; Ciszewski G; Park K; Ellingboe JW; Bloom J; Insaf S; Upeslacis J; Mansour TS; Krishnamurthy G; Damarla M; Pyatski Y; Ho D; Howe AY; Orlowski M; Feld B; O'Connell J J Med Chem; 2004 Dec; 47(26):6603-8. PubMed ID: 15588095 [TBL] [Abstract][Full Text] [Related]
11. Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics. Nutho B; Meeprasert A; Chulapa M; Kungwan N; Rungrotmongkol T J Biomol Struct Dyn; 2017 Jun; 35(8):1743-1757. PubMed ID: 27236925 [TBL] [Abstract][Full Text] [Related]
12. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. Prongay AJ; Guo Z; Yao N; Pichardo J; Fischmann T; Strickland C; Myers J; Weber PC; Beyer BM; Ingram R; Hong Z; Prosise WW; Ramanathan L; Taremi SS; Yarosh-Tomaine T; Zhang R; Senior M; Yang RS; Malcolm B; Arasappan A; Bennett F; Bogen SL; Chen K; Jao E; Liu YT; Lovey RG; Saksena AK; Venkatraman S; Girijavallabhan V; Njoroge FG; Madison V J Med Chem; 2007 May; 50(10):2310-8. PubMed ID: 17444623 [TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase. Chen KX; Vibulbhan B; Yang W; Sannigrahi M; Velazquez F; Chan TY; Venkatraman S; Anilkumar GN; Zeng Q; Bennet F; Jiang Y; Lesburg CA; Duca J; Pinto P; Gavalas S; Huang Y; Wu W; Selyutin O; Agrawal S; Feld B; Huang HC; Li C; Cheng KC; Shih NY; Kozlowski JA; Rosenblum SB; Njoroge FG J Med Chem; 2012 Jan; 55(2):754-65. PubMed ID: 22148957 [TBL] [Abstract][Full Text] [Related]
14. SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. Powers JP; Piper DE; Li Y; Mayorga V; Anzola J; Chen JM; Jaen JC; Lee G; Liu J; Peterson MG; Tonn GR; Ye Q; Walker NP; Wang Z J Med Chem; 2006 Feb; 49(3):1034-46. PubMed ID: 16451069 [TBL] [Abstract][Full Text] [Related]
15. Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase. Pierra Rouvière C; Amador A; Badaroux E; Convard T; Da Costa D; Dukhan D; Griffe L; Griffon JF; LaColla M; Leroy F; Liuzzi M; Loi AG; McCarville J; Mascia V; Milhau J; Onidi L; Paparin JL; Rahali R; Sais E; Seifer M; Surleraux D; Standring D; Dousson C Bioorg Med Chem Lett; 2016 Sep; 26(18):4536-4541. PubMed ID: 27520942 [TBL] [Abstract][Full Text] [Related]
16. Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids. de Vicente J; Hendricks RT; Smith DB; Fell JB; Fischer J; Spencer SR; Stengel PJ; Mohr P; Robinson JE; Blake JF; Hilgenkamp RK; Yee C; Zhao J; Elworthy TR; Tracy J; Chin E; Li J; Lui A; Wang B; Oshiro C; Harris SF; Ghate M; Leveque VJ; Najera I; Le Pogam S; Rajyaguru S; Ao-Ieong G; Alexandrova L; Fitch B; Brandl M; Masjedizadeh M; Wu SY; de Keczer S; Voronin T Bioorg Med Chem Lett; 2009 Oct; 19(19):5648-51. PubMed ID: 19700319 [TBL] [Abstract][Full Text] [Related]
17. 3-heterocyclyl quinolone inhibitors of the HCV NS5B polymerase. Kumar DV; Rai R; Brameld KA; Riggs J; Somoza JR; Rajagopalan R; Janc JW; Xia YM; Ton TL; Hu H; Lehoux I; Ho JD; Young WB; Hart B; Green MJ Bioorg Med Chem Lett; 2012 Jan; 22(1):300-4. PubMed ID: 22119470 [TBL] [Abstract][Full Text] [Related]
18. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. Hirashima S; Suzuki T; Ishida T; Noji S; Yata S; Ando I; Komatsu M; Ikeda S; Hashimoto H J Med Chem; 2006 Jul; 49(15):4721-36. PubMed ID: 16854079 [TBL] [Abstract][Full Text] [Related]
19. The discovery and structure-activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase. LaPorte MG; Draper TL; Miller LE; Blackledge CW; Leister LK; Amparo E; Hussey AR; Young DC; Chunduru SK; Benetatos CA; Rhodes G; Gopalsamy A; Herbertz T; Burns CJ; Condon SM Bioorg Med Chem Lett; 2010 May; 20(9):2968-73. PubMed ID: 20347591 [TBL] [Abstract][Full Text] [Related]
20. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. Venkatraman S; Bogen SL; Arasappan A; Bennett F; Chen K; Jao E; Liu YT; Lovey R; Hendrata S; Huang Y; Pan W; Parekh T; Pinto P; Popov V; Pike R; Ruan S; Santhanam B; Vibulbhan B; Wu W; Yang W; Kong J; Liang X; Wong J; Liu R; Butkiewicz N; Chase R; Hart A; Agrawal S; Ingravallo P; Pichardo J; Kong R; Baroudy B; Malcolm B; Guo Z; Prongay A; Madison V; Broske L; Cui X; Cheng KC; Hsieh Y; Brisson JM; Prelusky D; Korfmacher W; White R; Bogdanowich-Knipp S; Pavlovsky A; Bradley P; Saksena AK; Ganguly A; Piwinski J; Girijavallabhan V; Njoroge FG J Med Chem; 2006 Oct; 49(20):6074-86. PubMed ID: 17004721 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]